.png)
Professor Hubert Hondermarck
The University of Newcastle
$448,302
2025 - 2028
The Research
HER2+ breast cancers are currently treated with anti-HER2 targeted therapies, but resistance often develops, leading to fatal metastatic breast cancer. Therefore, there is a critical need for new treatment options for resistant HER2+ breast cancers.
In this project, we propose repurposing a known drug, already approved for the treatment of other cancers, for the treatment of HER2+ breast cancer resistant to current therapies. This strategy would be rapidly translated into clinical practice.
share
.svg)
